Considerations in selecting rapid-onset opioids for the management of breakthrough pain

Howard S SmithDepartments of Anesthesiology, Medicine, and Physical Medicine and Rehabilitation Albany Medical College, Albany, NY, USAAbstract: Breakthrough pain (BTP) is a transitory pain that occurs despite the use of long-term, around-the-clock analgesia. It is highly prevalent in certain popula...

Full description

Bibliographic Details
Main Author: Smith HS
Format: Article
Language:English
Published: Dove Medical Press 2013-03-01
Series:Journal of Pain Research
Online Access:http://www.dovepress.com/considerations-in-selecting-rapid-onset-opioids-for-the-management-of--a12380
id doaj-60852a0b14014a2e96e6dc5206ca61f8
record_format Article
spelling doaj-60852a0b14014a2e96e6dc5206ca61f82020-11-24T21:12:47ZengDove Medical PressJournal of Pain Research1178-70902013-03-012013default189200Considerations in selecting rapid-onset opioids for the management of breakthrough painSmith HSHoward S SmithDepartments of Anesthesiology, Medicine, and Physical Medicine and Rehabilitation Albany Medical College, Albany, NY, USAAbstract: Breakthrough pain (BTP) is a transitory pain that occurs despite the use of long-term, around-the-clock analgesia. It is highly prevalent in certain populations and places a significant burden on patients, their families, caregivers, and health-care systems. Despite its prevalence and impact, BTP is sometimes unrecognized and often undertreated. Various formulations of fentanyl – a rapid-onset opioid with short duration of action – are available for the management of BTP. The efficacy of formulations using transmucosal, transbuccal, sublingual, and intranasal administration routes has been demonstrated for BTP treatment in clinical trials. However, a lack of head-to-head trials evaluating their relative efficacy makes it challenging for physicians to reach informed decisions on the most efficacious intervention for individual patients. In the absence of clear data on the relative efficacy of fentanyl formulations, prescribing decisions need to be based on physician understanding and experience and product cost and availability, taking into account the individual patient's needs, the ability of the patient or caregivers to administer medication, and the patient's wishes. This review evaluates current pharmacologic methods of alleviating BTP and discusses factors that should be considered when selecting the most appropriate formulation for individual patients. With the range of fentanyl formulations available, it is now possible to successfully address BTP in the majority of patients.Keywords: rapid-onset opioid, breakthrough pain, pain, fentanylhttp://www.dovepress.com/considerations-in-selecting-rapid-onset-opioids-for-the-management-of--a12380
collection DOAJ
language English
format Article
sources DOAJ
author Smith HS
spellingShingle Smith HS
Considerations in selecting rapid-onset opioids for the management of breakthrough pain
Journal of Pain Research
author_facet Smith HS
author_sort Smith HS
title Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_short Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_full Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_fullStr Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_full_unstemmed Considerations in selecting rapid-onset opioids for the management of breakthrough pain
title_sort considerations in selecting rapid-onset opioids for the management of breakthrough pain
publisher Dove Medical Press
series Journal of Pain Research
issn 1178-7090
publishDate 2013-03-01
description Howard S SmithDepartments of Anesthesiology, Medicine, and Physical Medicine and Rehabilitation Albany Medical College, Albany, NY, USAAbstract: Breakthrough pain (BTP) is a transitory pain that occurs despite the use of long-term, around-the-clock analgesia. It is highly prevalent in certain populations and places a significant burden on patients, their families, caregivers, and health-care systems. Despite its prevalence and impact, BTP is sometimes unrecognized and often undertreated. Various formulations of fentanyl – a rapid-onset opioid with short duration of action – are available for the management of BTP. The efficacy of formulations using transmucosal, transbuccal, sublingual, and intranasal administration routes has been demonstrated for BTP treatment in clinical trials. However, a lack of head-to-head trials evaluating their relative efficacy makes it challenging for physicians to reach informed decisions on the most efficacious intervention for individual patients. In the absence of clear data on the relative efficacy of fentanyl formulations, prescribing decisions need to be based on physician understanding and experience and product cost and availability, taking into account the individual patient's needs, the ability of the patient or caregivers to administer medication, and the patient's wishes. This review evaluates current pharmacologic methods of alleviating BTP and discusses factors that should be considered when selecting the most appropriate formulation for individual patients. With the range of fentanyl formulations available, it is now possible to successfully address BTP in the majority of patients.Keywords: rapid-onset opioid, breakthrough pain, pain, fentanyl
url http://www.dovepress.com/considerations-in-selecting-rapid-onset-opioids-for-the-management-of--a12380
work_keys_str_mv AT smithhs considerationsinselectingrapidonsetopioidsforthemanagementofbreakthroughpain
_version_ 1716749945461014528